Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, completed a reverse merger with Olivia Ventures in a $60m deal. “This transaction provides the resources necessary to advance our lead program, CTX-471, through clinical development, advance our second program, CTX-8371, to the clinic and continue to develop our pipeline of next-generation monoclonal and multispecific antibody therapeutics. CTX-471 is currently being evaluated in a Phase 1 clinical trial in patients with solid tumors that have progressed after at least three months on an approved PD-1 or PD-L1 inhibitor - an area of important unmet need,” Thomas Schuetz, Compass Therapeutics Co-Founder and CEO.